Boehringer Ingelheim allocates COVID relief fund to support underserved communities and patients in India

India, May 18, 2021 – Boehringer Ingelheim is making available a Euro One Million COVID relief fund to enable sustenance and livelihoods of underserved and tribal communities, and address medical needs of patients in India, through the 2021-22 financial year. Since January 2020, the organization has been engaged in financial and medical relief for COVID care, sustaining the lives of people impacted by the pandemic conditions.

Boehringer Ingelheim through its Global Support Program aims to address current needs of vulnerable communities, balancing it with initiatives that secure their future.

“During these trying times, all of us at Boehringer Ingelheim are part of the collective effort in fighting COVID-19. Through our Global Support Program, we want to contribute with relevant means to the current situation and support especially those who need immediate assistance,” says Médard Schoenmaeckers, Global Head Communications & Public Affairs at Boehringer Ingelheim, overseeing the Global Support Program.

The relief package includes support to underserved and tribal communities in Coimbatore, Tamil Nadu, under ‘Making More Health’, Boehringer Ingelheim’s long-term social initiative. This program works on holistic development of village communities, enabling people to live healthier and empowered lives. A special focus on children’s development ensures the sustained well-being and future of the communities.

Vani Manja, Managing Director, Boehringer Ingelheim India said, “Boehringer Ingelheim is committed to people and patients in India. It takes all of us to tide over the current healthcare situation. Our relief package has been designed to support current medical needs and ensure that livelihoods of people in migrant and tribal communities in Maharashtra are sustained, to help them manage the unprecedented times.”

About Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at www.boehringer-ingelheim.com

Established in 2003, Boehringer Ingelheim India, manages the India and the neighboring markets operations of the global enterprise. The Company enables access to innovator products as part of its Human Pharma and Animal Health businesses. The focus Human Pharma therapy areas include diabetes, cardiovascular and respiratory conditions. www.boehringer-ingelheim.in

About Making More Health

Making More Health (MMH) is a global initiative by the pharmaceutical company Boehringer Ingelheim in cooperation with Ashoka, a non-governmental organization. Aiming to improve health for humans, animals and communities worldwide Making More Health pursues a multitude of approaches to finding solutions and tailoring these solutions to specific projects.

For further information, please contact –
Magline Rufina FR
Director – Communications, Boehringer Ingelheim India
Email: magline.rufina_f_r@boehringer-ingelheim.com

Shivani Joshi
Archetype
E-mail: Shivani.Joshi@Archetype.co
Mob: +91 9870908500